Are Novel Serum Biomarkers Informative?

John T. Wilkins, Donald M. Lloyd-Jones*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


To justify use in routine coronary heart disease (CHD) risk assessment, a novel serum biomarker must be specifically associated with future CHD events and add information beyond techniques currently available. Current risk assessment techniques are probabilistic and imperfect; however, to date, no novel serum biomarker has improved substantially on the current population-based risk stratification approach. Although limited trial-based data are available to assess the utility of biomarkers, insights gained from biomarkers may enhance clinical decision making. Continued basic science and population-based research into CHD biomarkers may help to further the capacity for CHD risk assessment.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalMedical Clinics of North America
Issue number1
StatePublished - Jan 2012


  • Coronary heart disease risk
  • Risk assessment
  • Serum biomarkers

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Are Novel Serum Biomarkers Informative?'. Together they form a unique fingerprint.

Cite this